Guizhou Cancer Hospital

Guiyang

0 studies enrolling now · 1 studies all time

What they study most

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Studies at this site

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling